CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma (Q39218849)

10 September 2017

CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma (English)

1 reference

10 September 2017

Yijun Xue

1

1 reference

10 September 2017

Gengqing Wu

2

1 reference

10 September 2017

Xiaoning Wang

3

1 reference

10 September 2017

Xiaofeng Zou

4

1 reference

10 September 2017

Guoxi Zhang

5

1 reference

10 September 2017

Rihai Xiao

6

1 reference

10 September 2017

Yuanhu Yuan

7

1 reference

10 September 2017

Dazhi Long

8

1 reference

10 September 2017

Jun Yang

9

1 reference

10 September 2017

Yuting Wu

10

1 reference

10 September 2017

Hui Xu

11

1 reference

10 September 2017

Folin Liu

12

1 reference

10 September 2017

Min Liu

13

1 reference

10 September 2017

30 December 2012

1 reference

10 September 2017

1 reference

10 September 2017

30

1 reference

10 September 2017

1

1 reference

10 September 2017

406

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0406-6

10 September 2017

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Mechanisms of MYC stabilization in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A is associated with human breast cancer aggressivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A is a predictor of poor prognosis in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

The role of CIP2A in oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A overexpression is associated with c-Myc expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Prognostic role of CIP2A expression in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A expression is increased in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A expression is elevated in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Functions of myc:max in the control of cell proliferation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

MYC in oncogenesis and as a target for cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

The Myc/Max/Mad network and the transcriptional control of cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Seeding and propagation of untransformed mouse mammary cells in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Modelling Myc inhibition as a cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

MYC is a metastasis gene for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

MYC regulation of a "poor-prognosis" metastatic cancer cell state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Widespread microRNA repression by Myc contributes to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

CIP2A is a target of bortezomib in human triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Increase in CIP2A expression is associated with doxorubicin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0406-6

Over-expression and amplification of the c-myc gene in human urothelial carcinoma

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis

1 reference

12 December 2020

Role of myc amplification and overexpression in cell growth, differentiation and death.

1 reference

12 December 2020

The molecular role of Myc in growth and transformation: recent discoveries lead to new insights.

1 reference

12 December 2020

CIP2A is overexpressed in esophageal squamous cell carcinoma

1 reference

12 December 2020

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

1 reference

12 December 2020

c-myc oncoprotein levels in bladder cancer

1 reference

12 December 2020

A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition

1 reference

12 December 2020

Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer

1 reference

12 December 2020

CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells

1 reference

12 December 2020

10.1007/S12032-012-0406-6

Identifiers

DOI

1 reference

10 September 2017

1 reference